Product Image

HGH Surge

Source Naturals
4.5
★ ★ ★ ★ ★
(862 ratings)
GABA 350 mg
Huperzine 50 mcg
Acetyl L-Carnitine 450 mg
Chromium 200 mcg
Deanol 100 mg
Lysine 750 mg
Niacin 400 mg
Product Image
Score60
5-HTP, GABA, acetyl-L-carnitine, ginkgo, and velvet bean give the formula clear mood and cognition relevance. The formula combines amino acids with huperzine A, acetyl L-carnitine, ginkgo, GABA, and serotonin- and dopamine-related ingredients, but many amounts are too low for their focused uses.
How scoring works
Quantity:150 Tablet(s) • (30 servings)
Goals:
Metabolism Boost
Mood Support

Score 60

5-HTP, GABA, acetyl-L-carnitine, ginkgo, and velvet bean give the formula clear mood and cognition relevance. The formula combines amino acids with huperzine A, acetyl L-carnitine, ginkgo, GABA, and serotonin- and dopamine-related ingredients, but many amounts are too low for their focused uses.
How scoring works
$29.22($0.97 per serving)
Pure Formulas
$ 29.22
iHerb
$ 30.20
Vitacost
$ 31.63
Report prices

Analysis

5-HTP, GABA, acetyl-L-carnitine, ginkgo, and velvet bean give the formula clear mood and cognition relevance. The combination reaches serotonin, inhibitory signaling, dopamine-related activity, and neuroprotective support.

The formula combines amino acids with huperzine A, acetyl L-carnitine, ginkgo, GABA, and serotonin- and dopamine-related ingredients, but many amounts are too low for their focused uses. Ginkgo, 5-HTP, velvet bean, and huperzine A create important concerns with blood-thinning, serotonergic, dopaminergic, or cholinergic medicines.

The HGH Surge formula is designed for another health purpose and has little direct weight-loss relevance. The listed nutrients or botanicals lack strong evidence for meaningful fat reduction in this context.

Who is it for
  • Adults seeking Mood Support support
  • People comfortable with a multi-ingredient tablet formula
  • Users who can review the ingredient list against medicines and existing supplements
Best for
  • Mood Support
  • Metabolism Boost
  • Mental Focus

Pros

  • 5-HTP, GABA, acetyl-L-carnitine, ginkgo, and velvet bean give the formula clear mood and cognition relevance
  • Strongest formulation fit is Mood Support
  • Main label amounts are disclosed for L-Citrulline, Dimethylaminoethanol Bitartrate, Ginkgo leaf extract
  • Includes a meaningful Chromium component

Cons

  • too low for their focused uses
  • Weak fit for Weight Loss
  • Several secondary ingredients add breadth without equally strong dose or form support
  • Long ingredient list makes the combined effects and trade-offs harder to predict

Warnings

  • Ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines.
  • Several co-actives improve value, while the included five-hydroxytryptophan can raise serotonin-related risk with antidepressants such as SSRIs or MAO inhibitors.

Nutrient quality

52 Moderate impact

Several amino acids and standardized cognitive actives have reasonable forms. Weak goal alignment, scattered dosing, aggressive nutrients, and a crowded design limit quality.

.

Ingredient transparency

80 Highest impact

Most active ingredients and their amounts are clearly listed. Daily directions, a complete excipient panel, and some form details are missing from the supplied data.

.

Customer satisfaction

64 Moderate impact

The aggregate rating is favorable and supported by solid feedback volume. Complaint-level experiences are unavailable, so repeated drawbacks and purpose fit remain uncertain.

.

Value for money

40 Lower impact

The high serving cost is difficult to justify from the documented formula. Crowding, weak alignment, or aggressive dosing further reduces value.

.
Report analysis

Goals

Metabolism Boost
Metabolism Boost
Impact
High effect
C+ Goal FitB- Strength of SupportC+ CoverageC- Formula Quality
Niacin · 400 mgAcetyl L-Carnitine · 450 mg

Acetyl L-carnitine and chromium directly address mitochondrial transport and glucose handling, giving the formula a meaningful metabolic core. The carnitine amount falls slightly below common focused doses, and the growth-hormone-oriented amino acids add limited evidence for the selected goal.

Acetyl L-carnitine hydrochloride and organic chromium forms are clearly identified, which strengthens delivery quality. The combination of 5-HTP, velvet bean, ginkgo, and huperzine A warrants review for users of serotonergic, dopaminergic, blood-thinning, or cholinergic medicines.

Study evidence
Acetyl L-Carnitine Adverse 1 study
Chromium Supportive 47 studies
Mood Support
Mood Support
Impact
High effect
B- Goal FitC Strength of SupportB CoverageC- Formula Quality
5-HTP · 50 mg

5-HTP, GABA, acetyl-L-carnitine, ginkgo, and velvet bean give the formula clear mood and cognition relevance. The combination reaches serotonin, inhibitory signaling, dopamine-related activity, and neuroprotective support.

GABA is well dosed, while 5-HTP is a starting amount and several amino acids are modest. The mix is broad but complex, especially for people using serotonin- or dopamine-active medicines.

Study evidence
5-HTP Supportive 9 studies
GABA Supportive 12 studies
Mental Focus
Mental Focus
Impact
Moderate effect
C+ Goal FitC Strength of SupportB- CoverageD+ Formula Quality
Acetyl L-Carnitine · 450 mgHuperzine · 50 mcg

Acetyl-L-carnitine, ginkgo, huperzine A, and DMAE create a clearly cognitive component within the larger formula. Several amounts are near or below common targets, and missing extract standardization reduces confidence in consistent effects.

The blend reaches multiple focus pathways but is not as cleanly designed as a dedicated nootropic. Ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines, while huperzine A and the included serotonergic or dopaminergic ingredients may interact with related medicines.

Study evidence
Acetyl L-Carnitine Supportive 7 studies
Ginkgo Supportive 28 studies
Huperzine Not classified

No linked studies yet.

Brain Health
Brain Health
Impact
Moderate effect
B- Goal FitC Strength of SupportB- CoverageD Formula Quality
Huperzine · 50 mcg

Huperzine A, acetyl L-carnitine, ginkgo, and DMAE give the formula direct cognitive relevance across cholinergic, energy, and circulation pathways. Several amounts are near or below common targets, while the ginkgo standardization and many secondary actives are not fully clear.

The wide blend may offer acute cognitive support, but it was designed around growth-hormone and amino-acid marketing rather than a focused brain-health plan. Ginkgo, huperzine A, 5-HTP, and velvet bean can create meaningful interaction concerns with blood-thinning, cholinergic, serotonergic, or dopaminergic medicines.

Study evidence
Acetyl L-Carnitine Supportive 19 studies
Ginkgo Supportive 90 studies
Huperzine Supportive 17 studies
Productivity Boost
Productivity Boost
Impact
Moderate effect
B- Goal FitC Strength of SupportB- CoverageF Formula Quality
Acetyl L-Carnitine · 450 mgAcetyl L-Carnitine · 450 mgHuperzine · 50 mcg

Huperzine A, acetyl L-carnitine, and ginkgo provide genuine cognitive relevance. Their benefits are diluted by a large growth-oriented amino-acid blend.

Huperzine A reaches a standard amount, while several supporting cognitive actives are below stronger targets. The combination may interact with serotonergic, dopaminergic, anticoagulant, antiplatelet, or cholinergic medicines.

Study evidence
Acetyl L-Carnitine Supportive 1 study
Acetyl L-Carnitine Supportive 1 study
Ginkgo Supportive 20 studies
Ginkgo Supportive 12 studies
Huperzine No effect 1 study
Cognitive Support
Cognitive Support
Impact
Moderate effect
C+ Goal FitC Strength of SupportC+ CoverageF Formula Quality
Huperzine · 50 mcgAcetyl L-Carnitine · 450 mg

Acetyl-L-carnitine, huperzine A, ginkgo, and DMAE provide credible mitochondrial, cholinergic, and circulation support. Several amounts are useful, but ginkgo lacks verified standardization and acetyl-L-carnitine and active DMAE sit slightly below stronger target ranges.

The much larger growth-hormone amino-acid blend dilutes the cognitive focus and mixes calming GABA and 5-HTP with activating velvet bean and cholinergic ingredients. Ginkgo, 5-HTP, velvet bean, and huperzine A can interact with blood-thinning, serotonergic, dopaminergic, or cholinergic medicines.

Study evidence
Acetyl L-Carnitine Supportive 20 studies
Deanol No effect 2 studies
Ginkgo Supportive 87 studies
Huperzine Supportive 22 studies

Ingredients

IngredientAmount per serving
Calories
20 Calorie(s)
Total Carbohydrates
1 Gram(s)
Protein
1 Gram(s)
Niacin (Inositol Nicotinate)
 400 mg
Chromium (Chromium Picolinate, Chromium Polynicotinate)
 200 mcg
L-Arginine L-Pyroglutamate
1 Gram(s)
L-Lysine Hydrochloride
750 mg
L-Glutamine
500 mg
Acetyl L-Carnitine HCl
450 mg
Glycine
400 mg
Gamma-Aminobutyric Acid
350 mg
L-Ornithine Hydrochloride
250 mg
L-Ornithine Ketoglutarate
250 mg
L-Citrulline
250 mg
Dimethylaminoethanol Bitartrate
100 mg
Ginkgo leaf extract (Flavone Glycosides, Terpene Lactones)
 100 mg
Velvet Bean
75 mg
5-HTP
50 mg
Huperzine A (Huperzia serrata extract)
 50 mcg
Adults 18–50 Women
Report overview
GABA · 350 mg OverallScore74
C+ Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyD- Value

The 350 mg GABA amount falls within the preferred standalone range, although no premium source or fermentation method is named. A five-tablet serving is cumbersome, and the broad amino acid and botanical blend makes GABA only one part of the formula. The serving cost is high for standard GABA, while 5-HTP and velvet bean introduce added interaction concerns with serotonin- or dopamine-active medicines.

View ingredientView products
Huperzine (Huperzia serrata extract) · 50 mcg OverallScore71
B+ Active Ingredient Quality & BioavailabilityA- Dose, Safety & Label TransparencyF Value

The clearly disclosed 50 mcg dose of Huperzine A is delivered in premeasured tablets and fits the intended range for cognitive support. The label names Huperzia serrata extract but does not show a standardized alkaloid percentage, leaving source consistency less certain. Cost efficiency for the target active is weak, and no cycling guidance is provided despite the potential for Huperzine A to accumulate with repeated use.

View ingredientView products
Acetyl L-Carnitine · 450 mg OverallScore67
A- Active Ingredient Quality & BioavailabilityB Dose, Safety & Label TransparencyF Value

The formula uses acetyl L-carnitine hydrochloride, but its dose falls just short of the usual target range. The large multi-ingredient blend raises the cost of obtaining an effective ALCAR amount without adding a clearly comparable premium cognitive ingredient. Because it combines 5-HTP, velvet bean, ginkgo, and huperzine A, people using serotonergic, dopaminergic, blood-thinning, or cholinergic medicines should review the blend with a clinician.

View ingredientView products
Loading alternative details
81 Performance

Double Strength 5-HTP 200 mg

NOW
<p>A clearly disclosed 5-HTP amount creates a more focused sleep and mood formula than the original crowded amino-acid and nootropic blend. Serotonergic medicines remain a specific concern because 5-HTP can further increase serotonin activity.</p>
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.
    Tan MS; Yu JT; Tan CC; Wang HF; Meng XF; Wang C; Jiang T; Zhu XC; Tan L · Journal of Alzheimer's disease : JAD · 2015
    Meta-analysis2,561 participants9 studies pooledBrain Health forGinkgo
  2. Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review.
    von Gunten A; Schlaefke S; Überla K · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2017
    Meta-analysis1,628 participants4 studies pooledCognitive Support Brain Health forGinkgo
  3. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.
    Malaguarnera M; Gargante MP; Cristaldi E; Vacante M; Risino C; Cammalleri L; Pennisi G; Rampello L · Digestive diseases and sciences · 2008
    Randomized trial125 participantsCognitive Support Brain Health forAcetyl L-Carnitine
  4. Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
    Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M · Neurology · 1991
    Randomized trial130 participantsBrain Health Cognitive Support forAcetyl L-Carnitine
  5. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode.
    Jangid P; Malik P; Singh P; Sharma M; Gulia AK · Asian journal of psychiatry · 2013
    Randomized trial70 participantsMood Support for5-HTP
  6. Oral intake of γ-aminobutyric acid affects mood and activities of central nervous system during stressed condition induced by mental tasks.
    Yoto A; Murao S; Motoki M; Yokoyama Y; Horie N; Takeshima K; Masuda K; Kim M; Yokogoshi H · Amino acids · 2012
    Randomized trial63 participantsMood Support Stress Relief forGABA
  7. Ginkgo biloba for cognitive impairment and dementia.
    Wieland LS; Ludeman E; Chi Y; Feinberg TM; Chen IH; Chen KH; Zhu Y; Wolverson E; Amri H · The Cochrane database of systematic reviews · 2026
    Meta-analysis10,613 participants82 studies pooledBrain Health Cognitive Support forGinkgo
  8. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach.
    Brooks JO; Yesavage JA; Carta A; Bravi D · International psychogeriatrics · 1998
    Randomized trial334 participantsCognitive Support forAcetyl L-Carnitine
  9. Alterations in gamma-aminobutyric acid and glutamate neurotransmission linked to intermittent theta-burst stimulation in depression: a sham-controlled study.
    Steinholtz L; Bodén R; Wall A; Lubberink M; Fällmar D; Persson J · Translational psychiatry · 2025
    Randomized trial42 participantsMood Support forGABA
  10. Mental impairment in aging: selection of patients, methods of evaluation and therapeutic possibilities of acetyl-L-carnitine.
    Passeri M; Iannuccelli M; Ciotti G; Bonati PA; Nolfe G; Cucinotta D · International journal of clinical pharmacology research · 1989
    Randomized trial30 participantsBrain Health forAcetyl L-Carnitine
  11. Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial.
    Truyens M; Lobatón T; Ferrante M; Bossuyt P; Vermeire S; Pouillon L; Dewint P; Cremer A; Peeters H; Lambrecht G; Louis E; Rahier JF; Dewit O; Muls V; Holvoet T; Vandermeulen L; Peeters A; Gonzales GB; Bos S; Laukens D; De Vos M · Gastroenterology · 2022
    Randomized trial166 participantsMood Support for5-HTP
  12. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome.
    Herrmann WM; Dietrich B; Hiersemenzel R · International journal of clinical pharmacology research · 1990
    Randomized trialBrain Health forAcetyl L-Carnitine
  13. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial.
    Malaguarnera M; Vacante M; Motta M; Giordano M; Malaguarnera G; Bella R; Nunnari G; Rampello L; Pennisi G · Metabolic brain disease · 2012
    Randomized trial61 participantsBrain Health Cognitive Support forAcetyl L-Carnitine
  14. Acetyl-L-carnitine in the treatment of mildly demented elderly patients.
    Passeri M; Cucinotta D; Bonati PA; Iannuccelli M; Parnetti L; Senin U · International journal of clinical pharmacology research · 1990
    Randomized trial60 participantsBrain Health Mental Focus forAcetyl L-Carnitine
  15. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.
    Riepe M; Hoerr R; Schlaefke S · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2025
    Meta-analysis782 participants4 studies pooledBrain Health Productivity Boost forGinkgo
  16. Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial.
    Cui M; You T; Zhao Y; Liu R; Guan Y; Liu J; Liu X; Wang X; Dong Q · Frontiers in pharmacology · 2023
    Randomized trial201 participantsBrain Health Productivity Boost forGinkgo
  17. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.
    Herrschaft H; Nacu A; Likhachev S; Sholomov I; Hoerr R; Schlaefke S · Journal of psychiatric research · 2012
    Randomized trial410 participantsBrain Health forGinkgo
  18. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis.
    Xing SH; Zhu CX; Zhang R; An L · Evidence-based complementary and alternative medicine : eCAM · 2014
    Meta-analysis825 participants10 studies pooledBrain Health Cognitive Support forHuperzine
  19. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
    Zhang Z; Wang X; Chen Q; Shu L; Wang J; Shan G · Zhonghua yi xue za zhi · 2002
    Randomized trial202 participantsBrain Health Cognitive Support forHuperzine
  20. Huperzine A associated with improved early postoperative cognitive function after neurosurgery under general anesthesia: a randomized clinical trial.
    Zhang Z; Shen Y; Li J; Tang Y; Zhou P; Ying T; Mo R; Ru Z; Zhao G; Zhu J; Li S; Zhao H · International journal of surgery (London, England) · 2026
    Randomized trial123 participantsBrain Health Cognitive Support forHuperzine
  21. Treatment with Huperzine A improves cognition in vascular dementia patients.
    Xu ZQ; Liang XM; Juan-Wu; Zhang YF; Zhu CX; Jiang XJ · Cell biochemistry and biophysics · 2012
    Randomized trial78 participantsBrain Health forHuperzine
  22. Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease.
    Gul A; Bakht J; Mehmood F · Journal of the Chinese Medical Association : JCMA · 2019
    Randomized trial100 participantsBrain Health forHuperzine
  23. Does l-citrulline supplementation and watermelon intake reduce blood pressure in middle-aged and older adults? A systematic review and meta-analysis of randomized controlled trials.
    Luo P; Chen J; Liu K; Zhang J · Clinical nutrition ESPEN · 2025
    Meta-analysis415 participants15 studies pooledCardiovascular Support forCitrulline
  24. Micronutrient Supplementation to Reduce Cardiovascular Risk.
    An P; Wan S; Luo Y; Luo J; Zhang X; Zhou S; Xu T; He J; Mechanick JI; Wu WC; Ren F; Liu S · Journal of the American College of Cardiology · 2022
    Meta-analysis883,627 participants884 studies pooledCardiovascular Support forCitrulline
  25. l-Citrulline supplementation improves O2 uptake kinetics and high-intensity exercise performance in humans.
    Bailey SJ; Blackwell JR; Lord T; Vanhatalo A; Winyard PG; Jones AM · Journal of applied physiology (Bethesda, Md. : 1985) · 2016
    Randomized trial10 participantsCardiovascular Support forCitrulline
  26. Effects of L-Citrulline Supplementation on Endothelial Function and Blood Pressure in Hypertensive Postmenopausal Women.
    Maharaj A; Fischer SM; Dillon KN; Kang Y; Martinez MA; Figueroa A · Nutrients · 2022
    Randomized trial25 participantsCardiovascular Support forCitrulline
  27. Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged men.
    Ochiai M; Hayashi T; Morita M; Ina K; Maeda M; Watanabe F; Morishita K · International journal of cardiology · 2012
    Randomized trial15 participantsCardiovascular Support forCitrulline
  28. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  29. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  30. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  31. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  32. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  33. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys.
    Torrioli MG; Vernacotola S; Peruzzi L; Tabolacci E; Mila M; Militerni R; Musumeci S; Ramos FJ; Frontera M; Sorge G; Marzullo E; Romeo G; Vallee L; Veneselli E; Cocchi E; Garbarino E; Moscato U; Chiurazzi P; D'Iddio S; Calvani M; Neri G · American journal of medical genetics. Part A · 2008
    Randomized trial63 participantsCognitive Support forAcetyl L-Carnitine
  34. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.
    Malaguarnera M; Gargante MP; Cristaldi E; Colonna V; Messano M; Koverech A; Neri S; Vacante M; Cammalleri L; Motta M · Archives of gerontology and geriatrics · 2008
    Randomized trial96 participantsCognitive Support forAcetyl L-Carnitine
  35. Senile dementia: treatment with deanol.
    Ferris SH; Sathananthan G; Gershon S; Clark C · Journal of the American Geriatrics Society · 1977
    Single-arm trial14 participantsCognitive Support forDeanol
  36. Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies.
    Blin O; Audebert C; Pitel S; Kaladjian A; Casse-Perrot C; Zaim M; Micallef J; Tisne-Versailles J; Sokoloff P; Chopin P; Marien M · Psychopharmacology · 2010
    Randomized trial24 participantsCognitive Support forDeanol
  37. Efficacy of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke: a predefined exploratory analysis of a multicenter, double-blind, randomized controlled trial.
    Tian X; Xu Q; Xia X; Zhang Y; Meng X; Wang A · Journal of neurology · 2024
    Randomized trial3,163 participantsCognitive Support forGinkgo
  38. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
    Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF · JAMA · 1997
    Randomized trial309 participantsCognitive Support Productivity Boost forGinkgo
  39. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial.
    Bachinskaya N; Hoerr R; Ihl R · Neuropsychiatric disease and treatment · 2011
    Randomized trial410 participantsCognitive Support forGinkgo
  40. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial.
    Ihl R; Bachinskaya N; Korczyn AD; Vakhapova V; Tribanek M; Hoerr R; Napryeyenko O; GOTADAY Study Group · International journal of geriatric psychiatry · 2013
    Randomized trial410 participantsCognitive Support forGinkgo
  41. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis.
    Zheng W; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Sun F; D'Arcy C; Meng X; Xiang YT · Human psychopharmacology · 2017
    Meta-analysis1,117 participants12 studies pooledCognitive Support forHuperzine
  42. [Drug evaluation of huperzine A in the treatment of senile memory disorders].
    Zhang RW; Tang XC; Han YY; Sang GW; Zhang YD; Ma YX; Zhang CL; Yang RM · Zhongguo yao li xue bao = Acta pharmacologica Sinica · 1992
    Randomized trial56 participantsCognitive Support forHuperzine
  43. Causes of hair loss and the developments in hair rejuvenation.
    Rushton DH; Norris MJ; Dover R; Busuttil N · International journal of cosmetic science · 2010
    Narrative reviewHair Health forLysine
  44. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial.
    Malaguarnera G; Pennisi M; Gagliano C; Vacante M; Malaguarnera M; Salomone S; Drago F; Bertino G; Caraci F; Nunnari G; Malaguarnera M · Hepatitis monthly · 2014
    Randomized trial62 participantsMental Focus Productivity Boost forAcetyl L-Carnitine
  45. [Psycho-functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration].
    Lino A; Boccia MM; Rusconi AC; Bellomonte L; Cocuroccia B · La Clinica terapeutica · 1992
    Non-randomized trial17 participantsMental Focus forAcetyl L-Carnitine
  46. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial.
    Arnold LE; Amato A; Bozzolo H; Hollway J; Cook A; Ramadan Y; Crowl L; Zhang D; Thompson S; Testa G; Kliewer V; Wigal T; McBurnett K; Manos M · Journal of child and adolescent psychopharmacology · 2008
    Randomized trial112 participantsMental Focus forAcetyl L-Carnitine
  47. Acetyl-L-carnitine for patients with hepatic encephalopathy.
    Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE · The Cochrane database of systematic reviews · 2019
    Meta-analysis398 participants5 studies pooledMental Focus forAcetyl L-Carnitine
  48. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review.
    Hort J; Duning T; Hoerr R · Neuropsychiatric disease and treatment · 2023
    Systematic review946 participants9 studies pooledMental Focus forGinkgo
  49. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Phytomedicine : international journal of phytotherapy and phytopharmacology · 2012
    Randomized trial216 participantsMental Focus forGinkgo
  50. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Pharmacopsychiatry · 1996
    Randomized trial216 participantsMental Focus forGinkgo
  51. Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial.
    Li S; Zhang X; Fang Q; Zhou J; Zhang M; Wang H; Chen Y; Xu B; Wu Y; Qian L; Xu Y · Stroke and vascular neurology · 2021
    Randomized trial348 participantsMental Focus forGinkgo
  52. Ginkgo biloba in the Aging Process: A Narrative Review.
    Barbalho SM; Direito R; Laurindo LF; Marton LT; Guiguer EL; Goulart RA; Tofano RJ; Carvalho ACA; Flato UAP; Capelluppi Tofano VA; Detregiachi CRP; Bueno PCS; Girio RSJ; Araújo AC · Antioxidants (Basel, Switzerland) · 2024
    Narrative review14 studies pooledMental Focus forGinkgo
  53. Low Bioavailability and High TMAO Production: Novel Insights Into Acetylcarnitine and Carnitine Metabolism.
    Krims-Davis K; Ozola M; Razzivina V; Gukalova B; Konrade I; Dambrova M; Liepinsh E · Molecular nutrition & food research · 2025
    Randomized trialMetabolism Boost forAcetyl L-Carnitine
  54. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.
    Anderson RA; Cheng N; Bryden NA; Polansky MM; Cheng N; Chi J; Feng J · Diabetes · 1997
    Randomized trial180 participantsMetabolism Boost forChromium
  55. Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Jamilian M; Asemi Z · Annals of nutrition & metabolism · 2016
    Randomized trial64 participantsMetabolism Boost forChromium
  56. A Comprehensive insight into the effect of chromium supplementation on oxidative stress indices in diabetes mellitus: A systematic review.
    Kooshki F; Tutunchi H; Vajdi M; Karimi A; Niazkar HR; Shoorei H; Pourghassem Gargari B · Clinical and experimental pharmacology & physiology · 2024
    Systematic review33 studies pooledMetabolism Boost forChromium
  57. Comparison of nutritional supplements in improving glycolipid metabolism and endocrine function in polycystic ovary syndrome: a systematic review and network meta-analysis.
    Hu X; Wang W; Su X; Peng H; Tan Z; Li Y; Huang Y · PeerJ · 2023
    Meta-analysis2,362 participants41 studies pooledMetabolism Boost forChromium
  58. [Chromium supplementation in patients with type 2 diabetes and high risk of type 2 diabetes: a meta-analysis of randomized controlled trials].
    San Mauro-Martin I; Ruiz-León AM; Camina-Martín MA; Garicano-Vilar E; Collado-Yurrita L; Mateo-Silleras Bd; Redondo Del Río Mde P · Nutricion hospitalaria · 2017
    Meta-analysis13 studies pooledMetabolism Boost forChromium
  59. The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial.
    Li S; Sutanto CN; Xia X; Kim JE · Nutrients · 2025
    Randomized trial30 participantsMood Support for5-HTP
  60. Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis.
    Javelle F; Lampit A; Bloch W; Häussermann P; Johnson SL; Zimmer P · Nutrition reviews · 2020
    Meta-analysis13 studies pooledMood Support for5-HTP
  61. Tryptophan and 5-hydroxytryptophan for depression.
    Shaw K; Turner J; Del Mar C · The Cochrane database of systematic reviews · 2002
    Systematic review64 participants2 studies pooledMood Support for5-HTP
  62. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study.
    Aliño JJ; Gutierrez JL; Iglesias ML · International pharmacopsychiatry · 1976
    Non-randomized trial30 participantsMood Support for5-HTP
  63. Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression.
    Deligiannidis KM; Kroll-Desrosiers AR; Mo S; Nguyen HP; Svenson A; Jaitly N; Hall JE; Barton BA; Rothschild AJ; Shaffer SA · Psychoneuroendocrinology · 2017
    Cohort study56 participantsMood Support forGABA
  64. The role of neurotransmitters in mediating the relationship between brain alterations and depressive symptoms in patients with inflammatory bowel disease.
    Wang J; Liu G; Xu K; Ai K; Huang W; Zhang J · Human brain mapping · 2023
    Case-control study69 participantsMood Support forGABA
  65. Occipital gamma-aminobutyric acid and glutamate-glutamine alterations in major depressive disorder: An mrs study and meta-analysis.
    Truong V; Cheng PZ; Lee HC; Lane TJ; Hsu TY; Duncan NW · Psychiatry research. Neuroimaging · 2021
    Observational studyMood Support forGABA
  66. Systematic review of gamma-aminobutyric-acid inhibitory deficits across the reproductive life cycle.
    Vigod SN; Strasburg K; Daskalakis ZJ; Blumberger DM · Archives of women's mental health · 2014
    Systematic review11 studies pooledMood Support forGABA
  67. [Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability].
    Kasper S; Schubert H · Fortschritte der Neurologie-Psychiatrie · 2009
    Meta-analysis10 studies pooledProductivity Boost forGinkgo
  68. Dietary Flavonoids and Human Cognition: A Meta-Analysis.
    Cheng N; Bell L; Lamport DJ; Williams CM · Molecular nutrition & food research · 2022
    Meta-analysis5,519 participants80 studies pooledProductivity Boost forGinkgo
  69. Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba.
    Elsabagh S; Hartley DE; File SE · Journal of psychopharmacology (Oxford, England) · 2005
    Randomized trial87 participantsProductivity Boost forGinkgo
  70. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial.
    Gavrilova SI; Preuss UW; Wong JW; Hoerr R; Kaschel R; Bachinskaya N; GIMCIPlus Study Group · International journal of geriatric psychiatry · 2015
    Randomized trial160 participantsProductivity Boost forGinkgo
  71. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers.
    Kennedy DO; Jackson PA; Haskell CF; Scholey AB · Human psychopharmacology · 2008
    Randomized trial78 participantsProductivity Boost forGinkgo
  72. Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial.
    Wessinger CM; Inman CL; Weinstock J; Weiss EP · International journal of exercise science · 2025
    Randomized trial15 participantsProductivity Boost forHuperzine
  73. The impact of 5-hydroxytryptophan supplementation on sleep quality and gut microbiota composition in older adults: A randomized controlled trial.
    Sutanto CN; Xia X; Heng CW; Tan YS; Lee DPS; Fam J; Kim JE · Clinical nutrition (Edinburgh, Scotland) · 2024
    Randomized trial30 participantsSleep Support for5-HTP
  74. Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial.
    Byun JI; Shin YY; Chung SE; Shin WC · Journal of clinical neurology (Seoul, Korea) · 2020
    Randomized trial40 participantsSleep Support forGABA
  75. Analysis of the Effects of Known Sleep-Support Supplements in Relation to Life Habits, Sleep Conditions, and Sleep Problems.
    Imafuku F; Yamamoto K; Tanaka E; Aoki R; Nishino S · Nutrients · 2023
    Randomized trial160 participantsSleep Support forGABA
  76. Reduced γ-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: a link to major depressive disorder?
    Plante DT; Jensen JE; Schoerning L; Winkelman JW · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012
    Case-control study40 participantsSleep Support forGABA
  77. GABA Supplementation, Increased Heart-Rate Variability, Emotional Response, Sleep Efficiency and Reduced Depression in Sedentary Overweight Women Undergoing Physical Exercise: Placebo-Controlled, Randomized Clinical Trial.
    Guimarães AP; Seidel H; Pires LVM; Trindade CO; Baleeiro RDS; Souza PM; Silva FGDE; Coelho DB; Becker LK; Oliveira EC · Journal of dietary supplements · 2024
    Randomized trial30 participantsSleep Support Stress Relief forGABA
  78. The effect of glycine administration on the characteristics of physiological systems in human adults: A systematic review.
    Soh J; Raventhiran S; Lee JH; Lim ZX; Goh J; Kennedy BK; Maier AB · GeroScience · 2024
    Systematic reviewSleep Support forGlycine
  79. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep.
    Bannai M; Kawai N · Journal of pharmacological sciences · 2012
    Narrative reviewSleep Support forGlycine
  80. The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers.
    Bannai M; Kawai N; Ono K; Nakahara K; Murakami N · Frontiers in neurology · 2012
    Clinical trial7 participantsSleep Support forGlycine
  81. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo.
    Kahn RS; Westenberg HG; Verhoeven WM; Gispen-de Wied CC; Kamerbeek WD · International clinical psychopharmacology · 1987
    Randomized trial45 participantsStress Relief for5-HTP
  82. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients.
    Schruers K; van Diest R; Overbeek T; Griez E · Psychiatry research · 2003
    Randomized trial48 participantsStress Relief for5-HTP
  83. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa.
    Smarius LJ; Jacobs GE; Hoeberechts-Lefrandt DH; de Kam ML; van der Post JP; de Rijk R; van Pelt J; Schoemaker RC; Zitman FG; van Gerven JM; Gijsman HJ · Journal of psychopharmacology (Oxford, England) · 2008
    Randomized trialStress Relief for5-HTP
  84. Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron.
    Jacobs GE; Kamerling IM; de Kam ML; Derijk RH; van Pelt J; Zitman FG; van Gerven JM · Journal of psychopharmacology (Oxford, England) · 2010
    Randomized trialStress Relief for5-HTP
  85. An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress.
    Emanuele E; Bertona M; Minoretti P; Geroldi D · Neuro endocrinology letters · 2011
    Single-arm trial15 participantsStress Relief for5-HTP
  86. Relieving occupational fatigue by consumption of a beverage containing γ-amino butyric acid.
    Kanehira T; Nakamura Y; Nakamura K; Horie K; Horie N; Furugori K; Sauchi Y; Yokogoshi H · Journal of nutritional science and vitaminology · 2011
    Clinical trial30 participantsStress Relief forGABA
  87. Cortical gamma-aminobutyric acid and glutamate in posttraumatic stress disorder and their relationships to self-reported sleep quality.
    Meyerhoff DJ; Mon A; Metzler T; Neylan TC · Sleep · 2014
    Case-control study45 participantsStress Relief forGABA
  88. Comparison of the effects of two amino acids, Gamma-aminobutyric acid (GABA) and L-theanine, on sedation, anxiety, and cognition in preoperative surgical patients - A randomized controlled study.
    Deshpande SS; Kurdi M; Baiju A; Athira AS; Sarasamma AG; Gangadharan AK · Journal of anaesthesiology, clinical pharmacology · 2025
    Randomized trial168 participantsStress Relief forGABA
  89. Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure.
    Díaz-Flores M; Cruz M; Duran-Reyes G; Munguia-Miranda C; Loza-Rodríguez H; Pulido-Casas E; Torres-Ramírez N; Gaja-Rodriguez O; Kumate J; Baiza-Gutman LA; Hernández-Saavedra D · Canadian journal of physiology and pharmacology · 2014
    Randomized trial60 participantsStress Relief forGlycine